Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

CYS Investments Inc (CYS), American International Group Inc (AIG), Staples, Inc. (SPLS): Here’s What These Quantitative Investors Have Been Buying

Page 1 of 2

Every quarter, many money managers have to disclose what they’ve bought and sold, via “13F” filings. Their latest moves can shine a bright light on smart stock picks.

Today, let’s look at Analytic Investors, founded in 1970 and based far from Wall Street, in Los Angeles. The company’s investment approach uses quantitative systems as it aims to maintain similar risk levels as its benchmarks but with stronger returns and lower risk while still racking up gains. It has even applied some of its quantitative processes to predicting Super Bowl outcomes, with a 9-1 record.

The company’s reportable stock portfolio totaled $5.6 billion in value as of June 30, 2013.

Interesting developments
So what does Analytic Investors’ latest quarterly 13F filing tell us? Here are a few interesting details:

CYS Investments IncThe biggest new holdings are Staples, Inc. (NASDAQ:SPLS) and Kohl’s Corporation (NYSE:KSS). Other new holdings of interest include CYS Investments Inc (NYSE:CYS), a mortgage REIT (mREIT) that recently yielded a 17% dividend yield (!). That’s partly due to the stock having fallen more than 30% over the past year. What’s up? Well, CYS’s second-quarter report featured a big loss as well as a drop in book value. Management blamed poor hedging, among other things. Analysts at Nomura recently lowered their price targets for the company substantially, from $13 to $8.

Among holdings in which Analytic Investors increased its stake was telecom company CenturyLink, Inc. (NYSE:CTL). It yields an appealing 6% (which reflects a dividend cut of about 25% ) and has been focusing more on rewarding shareholders via stock buybacks). The company landed a hefty Pentagon contract in April, with a possible 10-year value of $750 million, and has been moving into promising arenas such as cloud computing (via its purchase of Savvis). Having merged with Qwest, CenturyLink has substantial debt, topping $19 billion, but also significant free cash flow. Its EPS has been rising in the past few years, but revenue growth is mixed. The company is closing in on union contract agreements with 39% of its workers. It reports its quarterly earnings tomorrow, and putting union concerns behind it may boost investor confidence.

Analytic Investors reduced its stake in lots of companies, including Regions Financial Corporation (NYSE:RF), which tripled its dividend a few months ago. The bank’s first-quarter earnings topped analyst expectations, but also featured a drop in revenue, and its second quarter was solid but not exciting. Its improved performance in Federal Reserve stress tests has encouraged investors, as has its ambition to profit off mobile banking, but a website shutdown due to a cyber attack was worrisome.

Finally, Analytic Investors’ biggest closed positions included American International Group Inc (NYSE:AIG) and Viacom, Inc. (NASDAQ:VIAB). Other closed positions of interest include Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Synovus Financial Corp. (NYSE:SNV). Arena is battling in the weight-loss drug arena, with its Belviq formulation that has just begun selling. Belviq has been found to be less effective than some rivals, but also safer, and investors are hoping that insurers will reimburse most customers for it. A more effective form of Belviq is also in development. Meanwhile, Arena has other drugs in development, too, tackling conditions such as autoimmune diseases and hypertension.

Page 1 of 2
Loading Comments...